Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability
Abstract Background Due to the increasing expertise in transoral laser surgery and image-guided radiation therapy, treatment outcomes have recently improved in patients with early-stage glottic cancer. The objective of the current study was to evaluate intensity-modulated proton therapy (IMPT) as no...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13014-022-02144-w |
| _version_ | 1811188963139911680 |
|---|---|
| author | Thomas Held Henrik Franke Kristin Lang Tanja Eichkorn Sebastian Regnery Katharina Weusthof Lukas Bauer Karim Plath Gerhard Dyckhoff Peter K. Plinkert Semi B. Harrabi Klaus Herfarth Jürgen Debus Sebastian Adeberg |
| author_facet | Thomas Held Henrik Franke Kristin Lang Tanja Eichkorn Sebastian Regnery Katharina Weusthof Lukas Bauer Karim Plath Gerhard Dyckhoff Peter K. Plinkert Semi B. Harrabi Klaus Herfarth Jürgen Debus Sebastian Adeberg |
| author_sort | Thomas Held |
| collection | DOAJ |
| description | Abstract Background Due to the increasing expertise in transoral laser surgery and image-guided radiation therapy, treatment outcomes have recently improved in patients with early-stage glottic cancer. The objective of the current study was to evaluate intensity-modulated proton therapy (IMPT) as novel treatment option. Methods A total of 15 patients with T1-2N0 glottic squamous cell carcinoma, treated between 2017 and 2020, were evaluated. Toxicity was recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Results The majority were T1a/b tumors (66.7%) and no patient had lymph node or distant metastases. The median total dose was 70 Gy relative biological effectiveness (RBE) (range 66–70 Gy RBE). The one- and two-year OS and metastases-free survival were 100%. One patient developed local failure and received salvage laryngectomy. No higher-grade acute or late toxicity was reported. The mean number of CTCAE grade I and II overall toxicity events per patient was 4.1 (95%-[confidence interval] CI 3.1–5.3) and 1.0 (95%-CI 0.5–1.5). Conclusion High-precision proton therapy of T1-2N0 glottic cancer resulted in exceptional treatment tolerability with high rates of laryngeal function preservation and promising oncological outcome. IMPT has the potential to become a standard treatment option for patients with early-stage laryngeal cancer. |
| first_indexed | 2024-04-11T14:26:46Z |
| format | Article |
| id | doaj.art-b4bfb39d0e314a7baa74b18936529ee1 |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-04-11T14:26:46Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-b4bfb39d0e314a7baa74b18936529ee12022-12-22T04:18:48ZengBMCRadiation Oncology1748-717X2022-12-011711810.1186/s13014-022-02144-wIntensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerabilityThomas Held0Henrik Franke1Kristin Lang2Tanja Eichkorn3Sebastian Regnery4Katharina Weusthof5Lukas Bauer6Karim Plath7Gerhard Dyckhoff8Peter K. Plinkert9Semi B. Harrabi10Klaus Herfarth11Jürgen Debus12Sebastian Adeberg13Department of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Otorhinolaryngology, Head and Neck Surgery, University of HeidelbergDepartment of Otorhinolaryngology, Head and Neck Surgery, University of HeidelbergDepartment of Otorhinolaryngology, Head and Neck Surgery, University of HeidelbergDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalDepartment of Radiation Oncology, Heidelberg University HospitalAbstract Background Due to the increasing expertise in transoral laser surgery and image-guided radiation therapy, treatment outcomes have recently improved in patients with early-stage glottic cancer. The objective of the current study was to evaluate intensity-modulated proton therapy (IMPT) as novel treatment option. Methods A total of 15 patients with T1-2N0 glottic squamous cell carcinoma, treated between 2017 and 2020, were evaluated. Toxicity was recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Results The majority were T1a/b tumors (66.7%) and no patient had lymph node or distant metastases. The median total dose was 70 Gy relative biological effectiveness (RBE) (range 66–70 Gy RBE). The one- and two-year OS and metastases-free survival were 100%. One patient developed local failure and received salvage laryngectomy. No higher-grade acute or late toxicity was reported. The mean number of CTCAE grade I and II overall toxicity events per patient was 4.1 (95%-[confidence interval] CI 3.1–5.3) and 1.0 (95%-CI 0.5–1.5). Conclusion High-precision proton therapy of T1-2N0 glottic cancer resulted in exceptional treatment tolerability with high rates of laryngeal function preservation and promising oncological outcome. IMPT has the potential to become a standard treatment option for patients with early-stage laryngeal cancer.https://doi.org/10.1186/s13014-022-02144-wHead and neck cancerLaryngeal cancerSquamous cell carcinomaProton therapyGlottic cancerRadiotherapy |
| spellingShingle | Thomas Held Henrik Franke Kristin Lang Tanja Eichkorn Sebastian Regnery Katharina Weusthof Lukas Bauer Karim Plath Gerhard Dyckhoff Peter K. Plinkert Semi B. Harrabi Klaus Herfarth Jürgen Debus Sebastian Adeberg Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability Radiation Oncology Head and neck cancer Laryngeal cancer Squamous cell carcinoma Proton therapy Glottic cancer Radiotherapy |
| title | Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability |
| title_full | Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability |
| title_fullStr | Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability |
| title_full_unstemmed | Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability |
| title_short | Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability |
| title_sort | intensity modulated proton therapy for early stage glottic cancer high precision approach to laryngeal function preservation with exceptional treatment tolerability |
| topic | Head and neck cancer Laryngeal cancer Squamous cell carcinoma Proton therapy Glottic cancer Radiotherapy |
| url | https://doi.org/10.1186/s13014-022-02144-w |
| work_keys_str_mv | AT thomasheld intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT henrikfranke intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT kristinlang intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT tanjaeichkorn intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT sebastianregnery intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT katharinaweusthof intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT lukasbauer intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT karimplath intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT gerharddyckhoff intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT peterkplinkert intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT semibharrabi intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT klausherfarth intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT jurgendebus intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability AT sebastianadeberg intensitymodulatedprotontherapyforearlystageglotticcancerhighprecisionapproachtolaryngealfunctionpreservationwithexceptionaltreatmenttolerability |